Person Health
Person Health is transforming preventive healthcare with proprietary blood and breath technologies and AI to detect cancer earlier, more accurately, and affordably.
Person Health — Earlier Changes Everything
Person Health is making early disease detection more accurate, affordable, and accessible, starting with MyBloodQ Breast, a simple blood test for breast cancer.
Our belief is simple: Disease should never be a surprise.
Earlier. Accurate. Accessible. Finding cancer earlier can mean more treatment options, potentially less invasive care, and better outcomes. Yet early detection remains challenging and inaccessible for too many people.
MyBloodQ Breast uses proprietary molecular fingerprinting technology and advanced software to identify biological patterns associated with breast cancer through a simple blood draw. Built on years of research involving more than 4,000 development and training samples, MyBloodQ Breast demonstrated sensitivity and specificity in the mid-to-high 90% range across two blinded clinical case-control studies involving 437 participants, including promising detection of Stage 0 and Stage I cancers.
Speed matters, too. Unlike some blood-based cancer tests that take weeks to return results, MyBloodQ Breast is designed to deliver answers much faster, helping reduce the uncertainty and anxiety of waiting. Our technology is supported by published scientific research, with additional findings on multiple myeloma progression, developed with researchers at a leading global medical institution, selected for presentation at the American Society of Hematology (ASH) meeting in December 2026.
Scaling Commercialization
Earlier. Accurate. Accessible. Finding cancer earlier can mean more treatment options, potentially less invasive care, and better outcomes. Yet early detection remains challenging and inaccessible for too many people.
MyBloodQ Breast uses proprietary molecular fingerprinting technology and advanced software to identify biological patterns associated with breast cancer through a simple blood draw. Built on years of research involving more than 4,000 development and training samples, MyBloodQ Breast demonstrated sensitivity and specificity in the mid-to-high 90% range across two blinded clinical case-control studies involving 437 participants, including promising detection of Stage 0 and Stage I cancers.
Speed matters, too. Unlike some blood-based cancer tests that take weeks to return results, MyBloodQ Breast is designed to deliver answers much faster, helping reduce the uncertainty and anxiety of waiting. Our technology is supported by published scientific research, with additional findings on multiple myeloma progression, developed with researchers at a leading global medical institution, selected for presentation at the American Society of Hematology (ASH) meeting in December 2026.
Scaling Commercialization
We've launched our initial Research Use Only program with our first clinical customer, supported by our proprietary software platform. Our pipeline of prospective customers continues to grow, and we're engaging with leading U.S. healthcare systems. Person Health Clinical Laboratory has received its CLIA identification number, an important milestone toward clinical testing.
Our immediate focus is scaling MyBloodQ Breast commercialization. Our business model combines blood-based testing with software-enabled clinical workflows and partnerships, designed to make early detection more accessible, affordable, and scalable.
One Platform, Multiple Cancers
Breast cancer is our starting point, but MyBloodQ's underlying technology is being developed for lung, prostate, and colorectal cancers, with encouraging early research findings.
Person Health also has other proprietary biological signal platforms that create opportunities for future growth.
Our Larger Vision
We're developing software platforms that connect biological insights with clinical information, helping people and clinicians recognize changes in health earlier and take action sooner.
Our experienced team brings together expertise in healthcare software, diagnostics, medical devices, clinical research, and commercialization.
We're starting with breast cancer, but our vision is to make earlier, accurate, and accessible disease detection a reality for more people.
Our immediate focus is scaling MyBloodQ Breast commercialization. Our business model combines blood-based testing with software-enabled clinical workflows and partnerships, designed to make early detection more accessible, affordable, and scalable.
One Platform, Multiple Cancers
Breast cancer is our starting point, but MyBloodQ's underlying technology is being developed for lung, prostate, and colorectal cancers, with encouraging early research findings.
Person Health also has other proprietary biological signal platforms that create opportunities for future growth.
Our Larger Vision
We're developing software platforms that connect biological insights with clinical information, helping people and clinicians recognize changes in health earlier and take action sooner.
Our experienced team brings together expertise in healthcare software, diagnostics, medical devices, clinical research, and commercialization.
We're starting with breast cancer, but our vision is to make earlier, accurate, and accessible disease detection a reality for more people.
Person Health. Earlier changes everything.
Fundraise Details
Fundraise DetailsThis section is only visible to registered investors. Log in or register as an accredited investor to view.
Ready to Ask For Funding for your company?
Post a Funding RequestKey Facts
- Industry
- {{model.industry | ffIndustry}}
- Location
- {{model.city_state}}
- Year Founded
- {{model.year_founded}}
- Monthly Income
- {{model.monthly_income | ffIncome}}
- Website
- {{model.homepage_url}}